Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant resistance from managed care entities. The organizations are typically building limitations to coverage, such as steep price restrictions and PA that limit user opportunity. Analysts i